Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

Abstract

PURPOSE:

Gemcitabine and capecitabine are 2 anticancer drugs with a mechanism of action involving metabolism of pyrimidine nucleotides. Both are among the few agents active in patients with metastatic breast cancer (MBC) progressing after therapy with anthracyclines and taxanes. We have conducted a phase II trial of gemcitabine/capecitabine in patients with disease progression after treatment with anthracyclines and taxanes.

PATIENTS AND METHODS:

Treatment included gemcitabine 2000 mg/m2 on day 1 every 3 weeks and capecitabine 2500 mg/m2 daily (divided into 2 doses) on days 1-14 every 3 weeks; treatment was administered until disease progression or unacceptable toxicity was documented. All patients received concomitant oral pyridoxine 300 mg twice daily to prevent hand-foot syndrome (HFS). Of 39 patients treated, 33 had received previous treatment with anthracyclines, 6 had medical contraindication to anthracyclines, 35 had previously received taxanes, and 23 had received vinorelbine. Fourteen patients had previous high-dose chemotherapy with stem cell rescue and 5 had previously received trastuzumab. Patients were 31-79 years of age (median, 55 years) and, altogether, were given 386 courses of therapy (range, 1-36 courses per patient; median, 6 courses).

RESULTS:

Grade 3/4 toxicities included HFS (11 courses, 6 patients), stomatitis (6 courses, 2 patients), diarrhea (5 courses, 4 patients), anemia (5 courses, 2 patients), thrombocytopenia (5 courses, 2 patients), and neutropenia (1 course, 1 patient). Response rate (all 39 patients were evaluable) was 48.7% (partial response, n = 19; stable disease, n = 7; progressive disease, n = 13). Thirty-six patients died because of disease progression, and 3 are alive with progressive disease. Median follow-up was 26 months or until death. Median duration of response was 15 months (range, 3-26 months). Median time to disease progression was 5 months (range, 1-26 months). Median overall survival duration was 10 months (range, 1-37 months).

CONCLUSION:

In this cohort of patients heavily pretreated with anthracyclines and taxanes, the response rate to gemcitabine/capecitabine is encouraging, although response duration is limited.

• Authors: Raquel Andres, Jose Ignacio Mayordomo, Ricardo Lara, Rodrigo Lastra, Eugenia Ortega, Eduardo Polo, Julio Lambea, Dolores Isla, Alberto Saenz-Cusi, Pilar Escudero, Alejandro Tres
• Journal: Clinical breast cancer (Clin Breast Cancer) Vol. 6 Issue 2 Pg. 158-62 (Jun 2005) ISSN: 1526-8209 [Print] United States
• PMID: 16001994 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Anthracyclines
• Taxoids
• Deoxycytidine
• Capecitabine
• Fluorouracil
• Gemcitabine

Topics

• Adult
• Aged
• Anthracyclines (pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Capecitabine
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Disease Progression
• Drug Resistance, Neoplasm
• Female
• Fluorouracil (analogs & derivatives)
• Humans
• Infusions, Intravenous
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Taxoids (pharmacology, therapeutic use)
• Treatment Outcome
• Gemcitabine